Publications by authors named "R Perricone"
Article Synopsis
- The study compared the safety and effectiveness of etanercept and adalimumab biosimilars (SB4 and ABP501) with their original versions among patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in Italy from 2017 to 2020.
- Out of 891 patients, safety profiles were similar; however, biosimilars had higher discontinuation rates due to ineffectiveness, with retention rates at 24 months being 76.5% for biosimilars compared to 81.1% for originators.
- The findings suggest biosimilars are a viable, safe, and more affordable treatment option, offering
Introduction: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a highly prothrombotic reaction to COVID-19 (coronavirus disease 2019) adenoviral vector vaccines. Its distinct bleeding and thrombotic patterns compared with other platelet consumptive disorders remain unclear.
Methods: We performed a systematic review of the literature (PubMed and Embase) up to July 31, 2022, including case reports and case series providing nonaggregate data of VITT patients.
Background: Psoriatic arthritis (PsA) is a chronic, immune-mediated, spondyloarthropathy characterised by musculoskeletal signs and symptoms with associated joint pain and tenderness. The average worldwide PsA prevalence is 133/100,000, while in the Italian population is 90-420/100,000. Traditionally, nonsteroidal anti-inflammatory drugs, glucocorticoid, and disease-modifying antirheumatic drugs have been used in the treatment of PsA.
View Article and Find Full Text PDFObjectives: To compare real-world persistence, effectiveness and tolerability of ustekinumab versus TNF inhibitors (TNFi) in psoriatic arthritis (PsA).
Methods: One-year data from Italian subjects enrolled in the PsABio study (PsA patients receiving 1st- to 3rd-line treatment with ustekinumab or TNFi) were evaluated. Treatment persistence was analysed using Kaplan-Meier curves; hazard ratios (HR) of stopping treatment, and the corresponding 95% confidence intervals (CI), were computed through Cox regression models.
Article Synopsis
- Biologics have shown efficacy in treating Psoriatic Arthritis (PsA) in clinical trials, but more real-world evidence is needed to confirm their effectiveness in everyday clinical settings.
- The CHRONOS study was conducted in 20 Italian hospitals and included 399 patients, revealing that the most common biologic used was secukinumab, with a 71.8% response rate after 6 months.
- Results demonstrated significant improvements in secondary outcomes such as skin symptoms and joint inflammation, supporting the effectiveness of biologics for PsA in practical applications, aligning with previous trial findings.